Abstract 4503
Background
NAVYA is a validated online cancer informatics solution that combines artificial intelligence (AI) and rapid review (2 mins/case) by multi-disciplinary tumor board experts at Academic Medical Centers (AMC) to deliver multidisciplinary expert treatment plan to patients within 24 hours. Initially developed for patients in India without ready access to expertise, over 28,000 patients across 68 countries have since reached out to NAVYA. Prior research (SABCS and ASCO 2014-2018) showed, 1) 97% concordance of NAVYA with an AMC in India and in the US 2) 97% of patients experienced significant anxiety relief due to 24 hours turnaround time. NAVYA scales access to expertise unlike the limitations of synchronized 1 patient: 1 doctor consults in telemedicine.
Methods
Three patient centered outcomes (travel distance, cost and time to receive expert treatment plan) were studied. All consecutive patients who reached out to NAVYA between 1/1/17-1/31/19 but ultimately opted for in-person visit to an AMC were contacted by prospective phone follow up. This was compared to a numerically balanced random sample of patients who only used NAVYA to obtain treatment plans.
Results
Prospective phone follow-ups with 902 in-person patients and 901 NAVYA patients were analyzed. The groups did not differ significantly in demographics or disease characteristics. In-person patients and NAVYA patients differed significantly with respect to 1) median travel distance (761 miles, IQR (152 -1083 miles) vs. 0 miles (p < 0.05)) 2) travel related costs of $1250 [95% CI +/- $54.5] vs $105 online processing fee 3) total time to receipt of treatment plan (4.66 days, IQR (0.4 - 20.3 days) vs. 1.04 day IQR (0.4-2.5) (p < 0.05)).
Conclusions
Cancer informatics solutions that combine AI with human clinical expertise to generate multidisciplinary treatment plans tailored to an individual patient, and vetted by experts at AMC, scale ready access to expertise around the world. For patients with limited access to AMC, such solutions eliminate travel burden, and significantly reduce cost and wait time. This has significant implications for creating access to specialty expertise, globally.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4370 - Continental differences in pathologic response with neoadjuvant ipilimumab (IPI) plus nivolumab (NIVO) in patients with macroscopic stage III melanoma in the phase 2 OpACIN-neo trial.
Presenter: Irene Reijers
Session: Poster Display session 3
Resources:
Abstract
3230 - Comparable responses of melanoma at primary site and synchronous lymph node metastases upon neoadjuvant ipilimumab (IPI) and nivolumab (NIVO)
Presenter: Judith Versluis
Session: Poster Display session 3
Resources:
Abstract
3171 - Adjuvant Therapies for Stage III Melanoma: Benchmarks for Bringing Clinical Trials to Clinical Practice
Presenter: Tina HIEKEN
Session: Poster Display session 3
Resources:
Abstract
3493 - Mixture-cure modeling for resected stage III/IV melanoma in the phase 3 CheckMate 238 trial
Presenter: Jeffrey Weber
Session: Poster Display session 3
Resources:
Abstract
3036 - An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: a subgroup analysis of patients with brain metastasis
Presenter: Caroline Dutriaux
Session: Poster Display session 3
Resources:
Abstract
2233 - Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting
Presenter: Jean Jacques Grob
Session: Poster Display session 3
Resources:
Abstract
2435 - A Single Arm, Open Label, Phase II, Multicenter Study to Assess the Detection of the BRAF V600 Mutation on cfDNA from Plasma in Patients with Advanced Melanoma
Presenter: Piotr Rutkowski
Session: Poster Display session 3
Resources:
Abstract
1766 - Efficacy and Safety of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600 Mutation-positive Melanoma in the Real-World Setting – Interim results of the non-interventional COMBI-r study
Presenter: Carola Berking
Session: Poster Display session 3
Resources:
Abstract
2131 - Trial update: A randomized Phase Ib/II study of the selective small molecule Axl inhibitor Bemcentinib (BGB324) in combination with either dabrafenib/trametinib (D/T) or pembrolizumab in patients with metastatic melanoma
Presenter: Oddbjørn Straume
Session: Poster Display session 3
Resources:
Abstract
4074 - Analysis of pyrexia in patients (pts) treated with dabrafenib (D) and/or trametinib (T) across clinical trials
Presenter: Caroline Robert
Session: Poster Display session 3
Resources:
Abstract